KYTHERA Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA’s lead product, KYBELLA™, is the first and only approved non-surgical treatment for contouring moderate to severe submental fullness, commonly referred to as double chin. When injected into subcutaneous fat, KYBELLA™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. KYTHERA also licensed the worldwide rights to setipiprant (KYTH-105), an early-stage potential treatment for hair loss. KYTHERA was acquired by Allergan for approximately $2.1 billion in 2015.

Graduated in 2012